CelluTarget · Multifocal Motor Neuropathy · Clinical Trials
Phase 3
Recruiting
NCT05030428

Inclisiran (Leqvio) — siRNA PCSK9 inhibitor

Sponsored by Novartis ↗
View on ClinicalTrials.gov ↗
Timeline
Study Dates
Start Date
January 2022
Est. Completion
June 2027
Enrollment Target
16000 participants
Status
Recruiting
Study Design
Primary Endpoint
MACE composite in primary prevention population (no prior CV event)
Registry
ClinicalTrials.gov Record
Registry ID
NCT05030428
Direct Link
clinicaltrials.gov/NCT05030428 ↗
Related Treatment
Treatment Being Studied
Inclisiran (Leqvio) — siRNA PCSK9 inhibitor →